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The temporal relationship between the 
development of vein graft intimal hyperplasia 
and growth factor gene expression 
John R. Hoch, MD, Vida K. Stark, MS, and William D. Turnipseed, MD 
Madison, Wis. 
Purpose: Intimal hyperplasia is a common cause of obstructive stenosis after arterial 
reconstructive procedures. It has been postulated that growth factors elaborated by 
vascular wall cells regulate fibroproliferative changes that can cause graft failure. This 
study characterizes transforming rowth factor beta-1 (TGF-f~I) and platelet-derived 
growth factor-A chain (PDGF-A) mRNA transcript profiles and their temporal 
relationship to the development of intimal hyperplasia n vein grafts. 
Methods: Epigastric vein-to-common femoral artery interposition grafts were performed 
in male Lewis rats (350 to 450 gm) with standard microsurgical techniques. Grafts were 
harvested ati and 4 hours, i and 4 days, and I and 2 weeks (n = 5/time). Graft RNA was 
extracted, reverse-transcribed, and amplified by polymerase chain reaction with 
sense/antisense primers for TGF-[31 and PDGF-A (30 cycles). Polymerase chain reaction 
fragments were confirmed by Southern hybridization. 
Results: Variable induction of TGF-[31 gene transcription was evident in vein grafts at 1 
and 4 hours, with prominent mRNA expression from i day to 2 weeks. PDGF-A mRNA 
was detected in ungrafted control veins but was downregulated at 1 hour and absent at 
4 hours after grafting. PDGF-A transcription was upregulated by 1 day, with prominent 
expression from 4 days to i week. Early loss of PDGF-A mRNA correlated with the early 
denudation ofthe endothelium, whereas upregulation by 4 days was preceded by TGF-[~ 1 
mRNA expression. 
Conclusions: Upregulation of TGF-f~l and PDGF-A mRNA expression is detected invein 
grafts before the development of a quantifiable neointima, which occurs by 2 weeks in our 
model. This suggests a role for these growth factors in the development of vein graft 
intimal hyperplasia. (J Vasc SURG 1995;22:51-8.) 
The success of vascular reconstructive procedures 
is limited during their first 2 years by the develop- 
ment ofintimal hyperplasia within the healing artery 
wall or bypass graft. 1'2 The arterial intima or graft 
neointima becomes progressively thicker because of 
smooth muscle cell (SMC) migration/proliferation 
and extracellular matrix deposition, which ultimately 
may lead to restenosis, occlusion, or both. It is likely 
that the stimulus initiating this process of vascular 
remodeling stems from the injury resulting from the 
reconstructive procedure itself. It has been postulated 
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that intimal hyperplasia results from growth factor 
gene expression by vascular endothelial cells, resident 
SMC, and infiltrating leukocytes, whose gene prod- 
ucts then promote cell proliferation and migration, 
extracellular matrix production, angiogenesis, and 
further leukocyte recruitment, a-s 
In vivo, upregulation of transforming rowth 
factor-beta (TGF-[3) gene transcription has been 
demonstrated in injured rat carotid arteries. 6,7 In- 
ducible TGF-[3 expression has also been demon- 
strated in vitro in activated SMC, endothelial cells, 
and macrophages. 8n TGF-~I is a pleiotropic cy- 
tokine involved in inflammation and wound repair. 
Its effects include leukocyte chemotaxis, 12 regulation 
of SMC and endothelial cell proliferation, stimu- 
lation of the production of extracellular matrix 
components, i is and immtmosuppression. 12 
Another factor implicated in vascular wound 
healing and intimal hyperplasia is platelet-derived 
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growth factor (PDGF), a dimeric cytoldne with 
chemotactic and mitogenic effects. It is believed to 
play a role in the development of intimal plaque in 
atherosclerosis, a  well as in repair of the arterial wall 
after injury. 16-18 
Previously, we have used a rat epigastric vein- 
to-common femoral artery interposition graft model 
of intimal hyperplasia to examine the histologic 
changes that occur in the arterialized vein wall. 19 In 
this study, as an initial step in examining the role of 
TGF-[31 and PDGF-A in the development of vein 
graft intimal hyperplasia, we have used qualitative 
reverse-transcription p lymerase chain reaction (RT- 
PCR) to characterize both TGF-[31 and PDGF-A 
messenger ribonucleic acid (mRNA) transcript pro- 
files and their temporal relationship to the vein wall 
changes observed in our model. 
MATERIAL AND METHODS 
Microsurgery. Superficial epigastric vein-to- 
common femoral artery interposition grafts were 
placed into male Lewis retired breeder rats by use of 
standard microsurgical techniques as previously de- 
scribed.19 Briefly, each rat was anesthetized intraperi- 
toneally with ketamine (90 mg/kg) and xylazine 
(4 mg/kg). The right groin was incised, and the 
epigastric vein and femoral artery were isolated under 
original magnification × 10. An 8 mm length of 
relaxed vein was excised, gently irrigated with hepa- 
rinized (5 U/ml) saline solution, reversed, and 
interposed into a 3 mm arterial defect. Proximal and 
distal ends of both vessels were slightly distended and 
then aligned in the normal direction of flow. At each 
anastomosis, 8 to 10 interrupted sutures were placed 
by use of 10.0 nylon. Total ischemic time was 45 
minutes. After reperfusion and visual confirmation of 
patency, the wound was closed with 3.0 silk suture, 
and the animal was allowed to recover. Animal care 
complied with the "Principles of Laboratory Animal 
Care" (formulated by the National Society for 
Medical Research) and the Guide for the Care and Use 
of Laboratory Animals (NIH Publication No. 80-23, 
revised 1985). The animal survival rate was 98%, and 
the graft patency rate was 92%. 
Harvest. Arterialized vein grafts were harvested 
at 1 and 4 hours, 1 and 4 days, and 1 and 2 weeks. 
With identical methods, nongrafted contralateral 
epigastric veins were dissected as controls. Rat was 
anesthetized intraperitoneally with ketamine (90 
mg/kg) and xylazine (4 mg/kg). The graft (or control 
vein) was assessed for patency and gently dissected. 
After ligation of proximal and distal arterial seg- 
ments, the graft was excised at the anastomoses. For 
RT-PCR (five vessels/time point), the graft was 
flushed with sterile saline solution, minced, and 
immediately placed into 500 ~1 guanidinium isothio- 
cyanate solution. For histology and immunohis- 
tochemistry, the graft was infused with 7% gelatin to 
keep the lumen open, fixed in 10% formalin for 2 to 
3 hours, and embedded in paraffin. 
RNA extraction. After tissue homogenization, 
total RNA was extracted by use of a modified method 
of Czomczynski and Sacchi 2°,21 as previously de- 
scribed. 19 Briefly, tissue homogenate was treated 
with hot phenol and chloroform/isoamyl alcohol, 
with addition of glycogen to maximize RNA recov- 
ery. After centrifugation, the aqueous phase was 
removed, and the RNA was precipitated overnight 
with isopropyl alcohol. After centrifugation and 
alcohol washes, RNA was resuspended and precipi- 
tated overnight with 100% ethanol. Total yields were 
calculated by spectrophotometry. 
Reverse transcription. RNA was reverse-tran- 
scribed to first-strand complementary DNA by use 
of standard laboratory protocol. 19 Template RNA 
was combined, on ice, with oligo deoxythymidine 
primer (15-mer; 0.8 mg/ml; Oligos, Etc., Wilson- 
ville, Ore.), buffer, deoxyribonucleoside triphos- 
phates (dNTPs) (10 mmol/L each; Promega, Madi- 
son, Wis.) and Moloney murine leukemia virus 
reverse transcriptase (600 U; Gibco BRL, Gaith- 
ersburg, Md.). After incubation for 2 hours at 
42 ° C, the enzyme was inactivated by incubation 
at 94 ° C for 10 minutes. 
Polymerase chain reaction. Reverse-transcribed 
cDNA template from both graft and control tissue 
(500 ng) was combined, on ice, with equimolar 
amounts of sense and antisense oligonucleotide 
primers specific for TGF-131, PDGF-A, and 
G3PDH (20 txmol/L; Oligos, Etc.). In addition, 
dNTPs (10 mmol/L each; Promega), PCR buffer, 
and Taq polymerase (1to 2 U; Perkin-Elmer, Foster 
City, Calif.) were added. Mineral oil was layered on 
top of the PCR sample to minimize evaporation. 
With the "hot start" technique to increase speci- 
ficity, samples were transferred directly from ice into 
a 94 ° C thermal cycler (Perkin-Elmer) and subjected 
to 30 thermal cycles of denaturation (94 ° C, 1 
minute), annealing (60 ° C, 1 minute), and primer 
extension (72 ° C, 2 minutes). To ensure that initial 
target mRNA represents amplified product, we 
previously determined the linear range of amplifi- 
cation for each primer pair as a function of cycle 
number. Primers were based on known rat se- 
quences and were 20 to 28 nucleotides in length, 
having a melting temperature greater than 72 ° C 
(Table I). Rat G3PDH served as the internal 
positive control. 
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Table I. Oligonucleotide s quences for polymerase chain reaction and Southern hybridization 
Denomination Primer~probe Sequence (5' to 3') 
TGF-[31 5' oligo* 
3' oligo* 
Southern 
PDGF-A 5' oligo 
3' oligo 
Southern 
G3PDH 5' oligo* 
3' oligo* 
Southern 
CTFCAGCTCCACAGAGAAGAACTGC 
CACGATCATGTTGGACAACTGCTCC 
GTGTGTCCAGGCTCCA.AATGTAGGGGCAG 
CTCGAACTCAGATCCACAGCATCC 
CTGGACCTCTI'TCAATITTGGCTTCTTC 
CTTCCTCAATACTTCTCTTCCTGCGAATGG 
TGAAGGTCGGTGTCAACGGATITGGC 
CATGTAGGCCATGAGGTCCACCAC 
CCATTGATGACCAGCTTCCCATTCTCAGCC 
*Sequences available from Clontech, Palo Alto, Calif. 
Electrophoresis and Southern hybridization. 
Eight microliters of PCR product were loaded on 
1.8% agarose gels in 0.5 x tris-borate-EDTA buffer 
along with appropriate molecular weight standards. 
Gels were run at 85 V, 45 minutes, stained with 
ethidium bromide to visualize nucleic acids, and 
photographed. The DNA in the gels was then 
denatured in high salt, transferred to nylon filters 
(Zeta-probe; BioRad, Hercules, Calif.), and immo- 
bilized. After prehybridization to decrease back- 
ground, the DNA attached to the filters was hybrid- 
ized to a phosphorus 32-5' end-labeled oligonucle- 
otide probe at 55 ° C overnight. Each probe sequence 
was specific for TGF-[31, PDGF-A, or G3PDH 
(30-mer; 5 ng/ml; Oligos Etc.) and was internal to 
that of the PCR primers. After extensive washing, 
the filter was dried, and autoradiography was per- 
formed. 
Histology and immunohistochemistry. Mor- 
phologic studies and immunohistochemistry with 
monoclonal antibodies were used as previously de- 
scribed to examine grafts at these arly time points. 19 
Ten grafts per time point were analyzed. Briefly, 
paraffin-embedded graft sections (5 txm) were cut at 
500 txm intervals. Sections were deparaffinized, 
rehydrated, and stained with hematoxylin and eosin 
for morphologic examination. Sections were also 
stained with monoclonal antibodies with use of the 
avidin-biotin-peroxidase technique. Primary mouse 
monoclonal antibodies included ED-1 (Serotec) for 
monocytes/macrophages, asm-1 (Boeringer Mann- 
heim) for e~-actin, and OX-42 (Serotec) for rat 
endothelium. Antibody specificity was confirmed by 
staining with isotype-matched control antibody. 
RESULTS 
Graft structure. The native epigastric vein is a 
thin-walled vessel composed of an intima consisting 
of endothelial cells and their basement membrane, an 
internal elastic lamina, a thin media composed of 
scattered SMC and extracellular matrix, and an 
adventitia composed of connective tissue bundles and 
fibroblasts (Fig. 1). Previously, we have described the 
histologic changes undergone by arterialized vein 
grafts) 9One hour after arterialization, grafts experi- 
ence some loss of endothelium coincident with 
neutrophil adherence to the luminal surface. By 4 
hours, this luminal blanket of neutrophils i ubiqui- 
tous, and there is further loss of the endothelial 
monolayer (Fig. 2,A). Within 24 hours after surgery, 
the vein wall has become thickened and edematous, 
with a substantial increase in inflammatory neutro- 
phils and monocytes/macrophages. By 1 week, the 
endothelium has been restored and the vein wall is 
further thickened: areas of patchy medial necrosis 
combined with associated transmural inflammatory 
infiltrates result in the formation of a neointima of 
variable thickness and composition (Fig. 2,/3). A 
distinct organized neointima containing many in- 
flammatory cells, a clearly visible internal elastic 
lamina, cellular debris, and immature collagen can be 
quantified reproducibly by 2 weeks (Fig. 2,C)) 3 
Neointimal thickening is most pronounced in the 
perianastomotic regions. Studies with immunohis- 
tochemical staining demonstrate moderate to heavy 
transmural infiltrated macrophages between 4 days 
and 1 week (Fig. 3,/1). Large numbers ofmacropha- 
ges are visible within the neointima and the adventitia 
at 2 weeks (Fig. 3~B). These macrophages are in close 
apposition, but are not identical, to cells staining for 
asm-1, a marker for ~x-actin present in SMC (unpub- 
fished observations, 1994). 
In vivo TGF-[~ 1 gene expression. A summary of 
TGF-[31 mRNA levels from all RT-PCR experi- 
ments, graded by visual inspection of gels, is pre- 
sented in Table II. A representative scan of an 
ethidium bromide-stained gel of amplified TGF-[31 
products is presented in Fig. 4. Five grafts per time 
point were analyzed. TGF-[31 mRNA was weakly 
detected in one of five nongrafted epigastric veins 
examined and was variable in vein grafts at 1 and 4 
hours, appearing as a faint band in a few grafts. By i 
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Fig. 1. Light micrograph of native nongrafted rat epigastric vein. (Hematoxylin and eosin 
staining; original magnification x 250.) 
day, however, TGF-[31 mRNA was easily detected in
all grafts. This strong induction continued to be evi- 
dent from 1 day through 2 weeks. Previous experi- 
ments have detected persistent TGF-[31 mRNA 
within vein grafts as late as 12 weeks after surgery. 19 
G3PDH levels remained constant hroughout all 
time points, indicating that TGF-IB1 mRNA levels 
were not nonspecifically elevated. 
In vivo PDGF-A gene expression. The profile 
of PDGF-A mRNA transcription is presented in 
Table II, and a representative gelis shown in Fig. 4. 
Five grafts per time point were analyzed. Results 
showed that PDGF-A mRNA is constitutively ex- 
pressed in nongrafted rat epigastric veins. Interest- 
ingly, at 1 hour after bypass, PDGF-A message l vels 
appeared to diminish, and at 4 hours after grafting, 
there was no message detected in any grafts, even 
after 35 thermal cycles (data not shown). At 1 day, 
mKNA for PDGF-A was generally detectable again, 
although in a few grafts, message was still absent. By 
4 days after grafting, all tissue contained high 
PDGF-A mRNA levels. Between 1 week and 2 
weeks, detectable signal was decreased. Again, 
G3PDH levels remained constant, indicating specific 
PDGF-A mRNA elevation (data not shown). 
Southern hybridization. To show specificity of 
amplification, oligonucleotide probes for TGF-[31 
and PDGF-A were designed to be internal to the 
respective PCR primers. A representative autoradio- 
graph of confirmatory Southern hybridization is 
shown in Fig. 5. The results confirm that the PCR- 
amplified DNA products are indeed TGF-[31 and 
PDGF-A fragments. 
DISCUSSION 
In this study, we have qualitatively demonstrated 
upregulation of TGF-[31 and PDGF-A gene expres- 
sion in rat arterialized vein grafts. TGF-[31, a 
mukifunctional polypeptide important in cell regu- 
lation, has been implicated in vascular wound heal- 
ing, restenosis, and immune regulation. 6J'12 Nikol et 
al. 6 demonstrated the increased expression of 
TGF-~31 in human restenotic coronary artery lesions 
(from both saphenous vein grafts and coronary 
arteries) compared with primary coronary theroscle- 
rotic lesions. Infusion of anti-TGF-[31 antibody 
significantly decreased the neointimal esions in 
injured rat carotid arteries. 7 A decrease in TGF-[31 
mRNA levels correlated with the severity of chronic 
rejection as assessed by the development of intimal 
hyperplasia in rat aortic allografts (Dr. Debra 
Hullett; in conversation, 1994). To clarify the effect 
of TGF-[31 on the arterial wall in vivo, Nabel et al.22 
transfected an expression vector encoding human 
TGF-[31 into porcine arteries; the expression of 
TGF-[31 resulted in increased cellular proliferation i
both the intima and media. 
Our in vivo data are consistent with the concept 
that TGF-[31 gene expression is upregulated after 
vascular injury or disturbance. In our vein graft 
model, TGF-[31 mRNA is detected very early after 
grafting when inflammatory cells are infiltrating the 
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Fig. 2. Light micrographs of intimal hyperplasia in arterialized vein grafts. A, Section of 
4-hour vein graft illustrates neutrophil adhesion to luminal surface with loss of endothelial cells. 
(Hematoxylin and eosin staining; original magnification ×400.) B, Section of 1 week vein graft 
illustrates transmural inflammatory infiltrate. (Hematoxylin and eosin staining; original 
magnification x 250.) C, Section of 2-week vein graft illustrating well-defined, hypercellular 
neointima. (Hematoxylin and eosin staining; original magnification ×400.) L represents 
lumen; I represents intima; N represents neointima; M represents media; A represents 
adventitia; arrow indicates internal elastic lamina. 
Table  I I .  Summary of  TGF-[31 and PDGF-A  mRNA transcript profiles in arterialized vein grafts 
Time point TGF-181 No. PDGF-A No. 
0 (epigastric vein) - / (  + ) 5 + 5 
1 hour - /+  4 - / (+)  5 
4 hours + 5 - 4 
1 day + + 6 + 5 
4 days + + + 6 + + 5 
1 week + + + 5 + 4 
2 weeks + + 5 + 5 
- ,  Absent; +/ - ,  variable; +, low abundance; + +, medium abundance; + ÷ +, high abundance. 
Message levels graded by visual inspection f ethidium bromide-stained gels of PCR amplification products. 
vein wall. Nearly all types of  cells present at inflam- 
matory sites have been proven capable o f  synthesiz- 
ing TGF-13 l,  including monocytes/macrophages and
neutrophils. 1°'12as'23 The possibility that neutrophils 
are the initial source of  TGF-131 mRNA within the 
arterialized vein wall is suggested by their adhesion to 
the luminal surface by 1 to 4 hours after grafting. 
Alternatively, damaged, activated endothelial cells or 
stressed medial SMC may be induced during grafting 
to express TGF-131. Prominent TGF-131 mKNA 
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Fig. 3. Light micrographs of arterialized vein graft sec- 
tions stained with antimonocyte/macrophage antibodies. 
A, Immunostaining of 1-week vein graft demonstrates 
transmural infiltration of monocytes and macrophages 
(stained with ED-1 monoclonal ntibody). B, Immuno- 
staining of 2-week vein graft illustrates extravasated mac- 
rophages present in developing neointima nd adventitia. 
Positive immnnostaining appears black (arrows); note 
nuclei of other ceils not stained with ED-1. (Original 
magnification × 400.) L represents graft lumen; N repre- 
sents neointima; A// represents media; A represents adven- 
titia. 
levels are also detectable from 1 day through 1 week, 
the time when macrophages are the predominant cell 
type within the vein wall. Message for TGF-[31 
continues to be detected in 2 week grafts after much 
of the initial inflammatory esponse has subsided and 
the neointima isactively thickening. Potential sources 
of TGF-JM at this and later time points include 
persistent neointimal macrophages, regenerated en- 
dothelial cells, or altered neointimal SMC. Activated 
macrophages are lmown to constitutively secrete 
TGF-[3,1°as and in injured rat carotid arteries, most 
neointimal SMC produce intracellular TGF-~3. n The 
sources of TGF-I31 in arterialized vein grafts remain 
to be ascertained. 
In vitro, TGF-[31 can act o promote or inhibit 
SMC growth. 812'24 Majack et al. 25'26 showed that 
Fig. 4. RT-PCR analysis of amplified TGF-[31 (top) and 
PDGF-A (middle) messenger RNA. Shown are value 
inversion scans of ethidium bromide-stained agarose gels. 
G3PDH was used as internal control (bottom). EV 
represents epigastric vein. 
TGF-~3 stimulates proliferation of confluent arterial 
SMC while inhibiting proliferation at subconfluent 
cell density. TGF-~3 was also shown to increase 
PDGF-A gene expression i  arterial SMC, which ac- 
counted for the mitogenic activity ofTGF-~3. 25 Con- 
versely, Battegay et al. 24 showed the effect of TGF-[3 
on cultured arterial SMC to be independent of SMC 
density, but concentration-dependent. Low concen- 
trations ofTGF-f3-induced human arterial SMC pro- 
liferation by stimulating autocrine PDGF-AA secre- 
tion, whereas at high concentrations, TGF-~3 inhib- 
ited proliferation by downregulating PDGF receptor 
tx subunits. 24 It is possible that arterial and venous 
SMC respond ifferently to TGF-[3. In a study by Mii 
et al.27 using human saphenous vein SMC, TGF- 
[3 inhibited cell proliferation induced by PDGF but 
had no effect on uninduced cells. Also TGF-[3 inhib- 
ited PDGF-induced migration of SMC in a 
concentration-dependent manner. 
TGF-[3 also regulates the gene expression of 
extracellular matrix components. I -15 In in vitro 
experiments, TGF-~ stimulated collagen, elastin, and 
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fibronectin production. 28a4'~s In in vivo gene transfer 
experiments, expression of TGF-[31 resulted in in- 
creased procollagen production. = Majesky et al. n 
demonstrated in injured rat carotid arteries that 
fibronectin, collagen ot2(I), and collagen % (III) 
transcripts were increased at times when the neoin- 
tima was forming and at sites where TGF-[3 was 
detectable by immunostaining. Treatment of injured 
rat carotid arteries with anti-TGF-[31 antibody re- 
sulted in decreased neointimal lesions containing very 
little fibronectin and versican compared with non- 
treated controls.7 These studies upport he idea that 
TGF-[31, in addition to exerting effects on cellular 
proliferation, contributes to arterial remodeling by 
stimulating extracellular matrix production. In our 
vein graft model, 19 after 4 weeks the neointima 
becomes progressively ess cellular without loss of 
neointimal area, most likely because of synthesis of 
extracellular matrix, This later phase of neointimal 
development coincides with continued TGF-131 gene 
expression detected within the vein wall for up to 12 
weeks. 19 
PDGF, a dimeric polypeptide that stimulates 
SMC migration and proliferation, is secreted by 
platelets, macrophages, fibroblasts, SMC, and endo- 
thelial cells, all of which are present in arterialized 
vein grafts. 17 PDGF-A mRNA is constitutively 
expressed in rat arteries. 18 In this study we have 
shown that PDGF-A mRNA is also constitutively 
expressed in native epigastric veins. 
In rat carotid arteries, PDGF-A mRNA has been 
shown to be upregulated as early as 6 hours after 
injury; the mRNA and protein were localized to a 
subpopulation of neointimal SMCs located just 
below the luminal surface. I8 In a baboon prosthetic 
graft model of intimal thickening, Kraiss et  {tl. 29 
localized PDGF-A mRNA and protein to the endo- 
thelium and the first few layers of subendothelial 
SMC. Wilcox et a1.16 demonstrated PDGF-A mRNA 
in the intima of human atherosclerotic plaques. In 
our vein graft model, PDGF-A genc expression is not 
detectable by 4 hours after grafting, coinciding with 
the denudation of the endothelial cell monolayer. 
This finding leads us to propose that loss of endo- 
thelium accounts for the loss of PDGF-A mRNA 
signal. Of course, it is possible that perturbation of 
the resident cells transcribing PDGF-A mRNA 
creates transient conditions that favor instability and 
degradation of the message. Nonetheless, ignal is 
once again detectable by 1 day, suggesting a new 
source of PDGF-A. 
Studies of the matrix of prosthetic grafts have 
demonstrated a large number of macrophages stain- 
IH 4H 1D 4D IW 2W 
TGF-  
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Fig. 5. Autoradiograph of confirmatory Southern hybrid- 
ization. TGF-[31 and PDGF-A probes hybridize specifcally 
to their respective PCR-amplified DNA products. 
ing prominently for PDGF-A. 29 Macrophages may 
also be the primary source of PDGF-A gene expres- 
sion in arterialized vein grafts. After the initial loss of 
PDGF-A message, gene expression is upregulated 
from 1 to 4 days after surgery. Endothelium is only 
partially restored at these times. As previously 
discussed, TGF-[31 can stimulate PDGF-A gene 
expression i vascular SMC. Because pregulation of
TGF-[31 occurs in the vein wall before the return of 
detectable PDGF-A mRNA, it is tempting to specu- 
late that TGF-131 is the stimulus behind the subse- 
quent upregulation ofPDGF-A and that the SMC is 
the target. It is unclear from this study, however, 
which cells are responsible for the detected upregu- 
lation of both PDGF-A and TGF-[31 mRNA. The 
relatively few SMC observed in these vein grafts 
before 2 weeks, coupled with the observed hea W 
transmural infiltrates of monocytes/macrophages t 
these early time points suggest that it is the macro- 
phage. Future investigations will attempt to answer 
these questions by identifying TGF-[31 and PDGF-A 
within specific cells of the vein wall with a combina- 
tion of immunohistochemistry and in situ hybridiza- 
tion techniques. 
In summary, we have used qualitative RT-PCR to 
characterize TGF-[31 and PDGF-A mRNA profiles 
within healing arterialized vein grafts. Prominent 
TGF-[31 and PDGF-A mRNA expression is detected 
in vein grafts after arterialization, before the devel- 
opment of quantifiable intimal hyperplasia. This early 
upregulation of growth factor gene expression coin- 
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cides with the appearance of moderate to heavy 
transmural inflammatory cells, mainly macrophages, 
within the vein graft. TGF-131 gene expression 
continues after the development of intimal hyperpla- 
sia, which occurs by 2 weeks, whereas PDGF-A gene 
expression is decreased. These data suggest a poten- 
tial role for these growth factors as modulators of the 
vein's response to arterialization. 
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